Skip to content
10-Q

Quarterly Report

PLUS THERAPEUTICS, INC. PSTV

0001193125-26-226978

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 6.88M sh
Shares Diluted Q1 2026 · Mar 31, 2026 6.65M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 582.67K sh
Capex Q1 2026 · Mar 31, 2026 $818K
Capex Q1 2026 · Mar 31, 2025 $3K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$6.24M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$6.17M
Short Term Investments Q1 2026 · Mar 31, 2026 $12.09M
Short Term Investments Q1 2026 · Dec 31, 2025 $4.36M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $3.02M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.26M
Stockholders Equity Q1 2026 · Mar 31, 2026 $11.96M
Stockholders Equity Q1 2026 · Dec 31, 2025 $4M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$23.64M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$8.95M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.96M
Current Liabilities Q1 2026 · Dec 31, 2025 $12.31M
Total Liabilities Q1 2026 · Mar 31, 2026 $7.96M
Total Liabilities Q1 2026 · Dec 31, 2025 $12.33M
Current Assets Q1 2026 · Mar 31, 2026 $18.03M
Current Assets Q1 2026 · Dec 31, 2025 $15.17M
Total Assets Q1 2026 · Mar 31, 2026 $19.92M
Total Assets Q1 2026 · Dec 31, 2025 $16.33M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.05
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$29.86
Eps Basic Q1 2026 · Mar 31, 2026 −$1.05
Eps Basic restated Q1 2026 · Mar 31, 2025 −$29.86
Sga Expense Q1 2026 · Mar 31, 2026 $5.28M
Sga Expense Q1 2026 · Mar 31, 2025 $2.84M
Rd Expense Q1 2026 · Mar 31, 2026 $2.87M
Rd Expense Q1 2026 · Mar 31, 2025 $1.76M
Net Income Q1 2026 · Mar 31, 2026 −$6.95M
Net Income Q1 2026 · Mar 31, 2025 −$17.4M
Operating Income Q1 2026 · Mar 31, 2026 −$7.12M
Operating Income Q1 2026 · Mar 31, 2025 −$3.54M